StreetInsider.com News Articles

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Thu, 10 Sep 2026 08:00:00 -0400

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France –

-- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO --

BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company’s work in rare melanocortin-4

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Thu, 10 Sep 2026 08:00:00 -0400

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France –

-- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO --

Deutsche Bank Starts Rhythm Pharmaceuticals (RYTM) at Hold

Thu, 27 Aug 2026 16:36:27 -0400

Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Hold rating and a price target of $120.00.

For an analyst ratings summary and ratings history on Rhythm Pharmaceuticals click here. For more ratings news on Rhythm Pharmaceuticals click here.

Shares of Rhythm Pharmaceuticals closed at $111.87 yesterday.

Rhythm gets Japan approval for obesity drug Imcivree

Mon, 24 Aug 2026 08:03:23 -0400

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that Japan's Ministry of Health, Labour and Welfare has granted marketing authorization to Imcivree (setmelanotide) for the treatment of acquired hypothalamic obesity, according to a company statement.

Imcivree, a melanocortin-4 receptor agonist, is described by Rhythm as the first therapy approved in Japan for this condition. The company estimates between 5,000 and 8,000 people in Japan are living with acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by injury to the hypothalamus.

Rhythm expects to commercially launch Imcivree in Japan before the end of 2026, pending final pricing determination.

The approval is

Rhythm gets Japan approval for obesity drug Imcivree

Mon, 24 Aug 2026 08:03:23 -0400

Rhythm expects to commercially launch Imcivree in Japan before the end of 2026, pending final pricing determination.

The approval is

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Mon, 24 Aug 2026 08:00:00 -0400

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --

-- Commercial launch in Japan expected by end of 2026, pending final pricing determination --

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization to IMCIVREE^® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO).

IMCIVREE, a melanocortin-4 receptor (MC4R) agonist which received

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Mon, 24 Aug 2026 08:00:00 -0400

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan --

-- Commercial launch in Japan expected by end of 2026, pending final pricing determination --

IMCIVREE, a melanocortin-4 receptor (MC4R) agonist which received

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 17 Filed by: Joshi Manher

Tue, 18 Aug 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260818/26945615.html

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 17 Filed by: Joshi Manher

Tue, 18 Aug 2026 17:35:00 -0400

si-local-file:///var/storage/secattach/20260818/26945615.html

Form 3 RHYTHM PHARMACEUTICALS, For: Aug 17 Filed by: Joshi Manher

Tue, 18 Aug 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260818/26945452.html

Form 3 RHYTHM PHARMACEUTICALS, For: Aug 17 Filed by: Joshi Manher

Tue, 18 Aug 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260818/26945452.html

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 13 Filed by: Shulman Joseph

Mon, 17 Aug 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26939115.html

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 13 Filed by: Shulman Joseph

Mon, 17 Aug 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26939115.html

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 13 Filed by: Garfield Alastair

Mon, 17 Aug 2026 17:58:00 -0400

si-local-file:///var/storage/secattach/20260817/26939104.html

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 13 Filed by: Garfield Alastair

Mon, 17 Aug 2026 17:58:00 -0400

si-local-file:///var/storage/secattach/20260817/26939104.html

Rhythm Pharmaceuticals names Manher Joshi as chief medical officer

Mon, 17 Aug 2026 08:00:53 -0400

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) has appointed Manher "AJ" Joshi, M.D., as Chief Medical Officer, effective Aug. 17, according to a company statement.

Dr. Joshi joins Rhythm from Soleno Therapeutics, where he served as Chief Development Officer. His prior roles include Chief Medical Officer at Neurona Therapeutics and Executive Vice President, Chief Medical Officer and Head of Clinical Development at Atara Biotherapeutics. Earlier in his career, he held positions at Allergan Medical, Hunt Bioventures, Synageva BioPharma Corp., Genzyme and HealthBanks.

Dr. Joshi holds a B.A. and M.D. from Boston University and Boston University School of Medicine and completed a residency in Internal

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Mon, 17 Aug 2026 08:00:00 -0400

BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17.

“We are excited to welcome AJ to Rhythm as we enter a new stage of growth and continue to expand our global impact for patients living with rare neuroendocrine diseases,” said David Meeker, M.D., Rhythm Chairman, President and Chief Executive Officer. “AJ brings more than two decades of leadership and experience from

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Mon, 17 Aug 2026 08:00:00 -0400

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 13 Filed by: Lee Jennifer Kayden

Fri, 14 Aug 2026 19:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26933189.html

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 13 Filed by: Lee Jennifer Kayden

Fri, 14 Aug 2026 19:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26933189.html

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 12 Filed by: Mazabraud Yann

Fri, 14 Aug 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26933188.html

Form 4 RHYTHM PHARMACEUTICALS, For: Aug 12 Filed by: Mazabraud Yann

Fri, 14 Aug 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26933188.html

Form 144 RHYTHM PHARMACEUTICALS, Filed by: Garfield Alastair

Thu, 13 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260813/26922361.html

Form 144 RHYTHM PHARMACEUTICALS, Filed by: Garfield Alastair

Thu, 13 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260813/26922361.html

Form 144 RHYTHM PHARMACEUTICALS, Filed by: Shulman Joseph

Thu, 13 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260813/26922162.html